Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1-(3-BIPHENYLYL)PIPERAZINE is an organic compound with the molecular formula C18H20N2. It is a derivative of piperazine, featuring a biphenyl group attached to the first carbon atom. 1-(3-BIPHENYLYL)PIPERAZINE is known for its potential applications in the pharmaceutical industry due to its ability to interact with specific receptors in the human body.

115761-61-0

Post Buying Request

115761-61-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

115761-61-0 Usage

Uses

Used in Pharmaceutical Industry:
1-(3-BIPHENYLYL)PIPERAZINE is used as a reactant for the preparation of aralkyl piperazine derivatives. These derivatives are designed to target serotonin reuptake inhibitory and 5-HT1A/5-HT7 receptors, which play a crucial role in the treatment of various psychiatric and neurological disorders, such as depression, anxiety, and schizophrenia. By modulating the activity of these receptors, 1-(3-BIPHENYLYL)PIPERAZINE and its derivatives can potentially improve the symptoms and management of these conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 115761-61-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,5,7,6 and 1 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 115761-61:
(8*1)+(7*1)+(6*5)+(5*7)+(4*6)+(3*1)+(2*6)+(1*1)=120
120 % 10 = 0
So 115761-61-0 is a valid CAS Registry Number.
InChI:InChI=1/C16H18N2/c1-2-5-14(6-3-1)15-7-4-8-16(13-15)18-11-9-17-10-12-18/h1-8,13,17H,9-12H2

115761-61-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-Biphenyl-3-yl-piperazine

1.2 Other means of identification

Product number -
Other names 1-(3-phenylphenyl)piperazine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:115761-61-0 SDS

115761-61-0Relevant articles and documents

MONOACYLGLYCEROL LIPASE INHIBITORS

-

Paragraph 0111-0112; 0141; 0153-0154; 0204-0205, (2021/09/09)

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

Multitargeted Compounds Derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-Acetamides as Candidates for Effective Anticonvulsant and Antinociceptive Agents

Abram, Micha?,Kamiński, Krzysztof,Kamiński, Rafa? M.,Latacz, Gniewomir,Lubelska, Annamaria,Mogilski, Szczepan,Rapacz, Anna

, p. 1996 - 2008 (2020/07/14)

We developed a focused set of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant and antinociceptive properties. These hybrid compounds demonstrated broad-spectrum protective activity in a range of mouse models, such as the maximal electroshock (MES) test, the pentylenetetrazole-induced seizures (scPTZ), and the 6 Hz (32 mA) seizures. Compound 22 showed the most potent anticonvulsant activity (ED50 MES = 23.7 mg/kg, ED50 6 Hz (32 mA) = 22.4 mg/kg, ED50 scPTZ = 59.4 mg/kg). In addition, 22 revealed potent efficacy in the formalin-induced tonic pain. These in vivo activities of 22 are likely mediated by several targets and may result from the inhibition of central sodium/calcium currents and transient receptor potential vanilloid 1 (TRPV1) receptor antagonism. Finally, the lead compound 22 revealed drug-like absorption, distribution, metabolism, excretion, toxicity (ADME-Tox) properties in the in vitro assays, making it a potential candidate for further development in epilepsy and neuropathic pain indications.

DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO

-

Page/Page column 43, (2019/02/25)

The invention relates to inhibitors of dihydrofolate reductase and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. falciparum, T. brucei, or L. major infections, using novel inhibitors of the invention.

COMPOSITIONS AND METHODS FOR TREATING INFECTIONS

-

Page/Page column 42, (2017/12/28)

The invention relates to inhibitors of dihydrotolate reductase and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. falciparum, T. hrucei, or L. major infections, using the novel inhibitors of the invention.

Discovery of Potent and Selective Leads against Toxoplasma gondii Dihydrofolate Reductase via Structure-Based Design

Welsch, Matthew E.,Zhou, Jian,Gao, Yueqiang,Yan, Yunqing,Porter, Gene,Agnihotri, Gautam,Li, Yingjie,Lu, Henry,Chen, Zhongguo,Thomas, Stephen B.

supporting information, p. 1124 - 1129 (2016/12/16)

Current treatment of toxoplasmosis targets the parasite’s folate metabolism through inhibition of dihydrofolate reductase (DHFR). The most widely used DHFR antagonist, pyrimethamine, was introduced over 60 years ago and is associated with toxicity that can be largely attributed to a similar affinity for parasite and human DHFR. Computational analysis of biochemical differences between Toxoplasma gondii and human DHFR enabled the design of inhibitors with both improved potency and selectivity. The approach described herein yielded TRC-19, a promising lead with an IC50 of 9 nM and 89-fold selectivity in favor of Toxoplasma gondii DHFR, as well as crystallographic data to substantiate in silico methodology. Overall, 50% of synthesized in silico designs met hit threshold criteria of IC50 2-fold selectivity favoring Toxoplasma gondii, further demonstrating the efficiency of our structure-based drug design approach.

CETP INHIBITORS

-

Page/Page column 155, (2008/06/13)

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I

4-benzylpiperazines useful as neuroleptics

-

, (2008/06/13)

Compounds of formula (I) in which the broken line forms a phenyl, naphthyl, pyridyl, indolizine, pyrrolo[1,2-a]pyrazine, pyrrolo[1,2-a]pyrimidine or pyrrolo[1,2-c]pyrimidine ring-system, R=H, halogen, OH, alkyl, alkyloxy or alkylthio, R'=H, halogen, alkyl, alkyloxy, alkylthio, CN or CF3, n and p=1, 2 or 3, the alkyl radicals having 1 to 4 C in a straight or branched chain. These products are useful as neuroleptics. STR1

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 115761-61-0